Experimental Cellular Pathology

实验细胞病理学核心旨在为研究人员提供集中的病理服务，包括免疫组织化学（IHC）和流式细胞术（FCM）程序，以支持所有四个项目。该资源结合了UAMS病理学部门与骨髓瘤研究和治疗研究所的专业知识和设施。将这些核心服务集中起来将避免每个调查人员在自己的实验室中建立这些服务的需要，并将有提供统一程序和有效使用材料和国会设备的额外好处。核心将解决以下具体目标：具体目标1：为每个P01项目的研究人员提供病理服务。具体来说，这将包括IHC和激光捕获显微解剖（LCM）。IHC服务将对项目1提供的患者样本进行，并用于支持项目1、2和3，以及项目2和4的体内动物模型研究。组织切片免疫组化的一个主要优点是组织的地形保持完整，形态学和免疫学特征可以整合，以便对骨髓结构进行微观解剖分析。LCM服务将有助于项目1和项目4，其中的研究将检查局灶性和间质性疾病模式以及骨髓微环境。专项目标2：构建组织微阵列（TIVIAs）。该核心的一个核心方面将是使用来自新患者以及项目1中纳入治疗方案的患者的材料构建tma。基因表达谱和蛋白质组学在POI中发挥着核心作用，通过使用诸如TMAs之类的材料，Core E将通过协助项目1，与Core C一起，在验证通过这些技术鉴定的与肿瘤细胞/骨髓微环境相关的关键基因和蛋白质方面发挥重要作用。具体目标3：提供流式细胞术服务，以验证微小残留疾病监测的新标记，以及具有独特遗传和生物学特性的骨髓瘤亚群的表征和鉴定。最近在恶性浆细胞中发现的异常免疫表型，以及识别和表征甚至较小的细胞亚群的独特能力，使FCM成为实现项目1所描述目标的理想技术。FCM还将用于项目2中开发的扩增NK细胞制剂的免疫表型表征。

The Experimental Cellular Pathology Core is designed to provide investigators with centralized pathologic services, including immunohistochemical (IHC) and flow cytometric (FCM) procedures in support of all four projects. This resource combines the expertise and facilities of the UAMS Department of Pathology with those of the Myeloma Institute for Research and Therapy. Centralizing these core services will avoid the need for each investigator to establish them in their own laboratories and will have the added benefit of providing for uniformity of procedures and efficient use of materials and capitol equipment. The core will address the following specific aims: Specific Aim 1: Provide pathology services to investigators in each P01 project. Specifically, this will include IHC and laser capture microdissection (LCM). IHC services will be performed on patient samples provided by Project 1 and utilized in support of Projects 1, 2 and 3 as well as on in vivo animal model studies in Projects 2 and 4. A major advantage of tissue section IHC is that the topography of the tissue remains intact and morphologic and immunologic features can be integrated to allow for microanatomic analysis of the bone marrow architecture. LCM services will be instrumental in Projects 1 and 4 where studies will examine focal and interstitial disease patterns as well as the marrow microenvironment. Specific Aim 2: Construct tissue microarrays (TIVIAs). A central aspect of the core will be the construction of TMAs using material derived from new patients as well as patients enrolled onto treatment protocols in Project 1. Gene expression profiling and proteomics play central roles in the POI and by using materials such as the TMAs, Core E will provide an important function by assisting Project 1, in conjunction with Core C, in the validation of key genes and proteins relating to the tumor cell/bone marrow microenvironment identified through these technologies. Specific Aim 3: Provide flow cytometry services to validate novel markers of minimal residual disease monitoring, and for characterization and identification of myeloma subpopulations with distinct genetic and biologic properties. The relatively recent identification of aberrant immunophenotypes in malignant plasma cells and the unique ability of to identify and characterize even minor cellular subpopulations makes FCM an ideal technology to accomplish the goals delineated in Project 1. FCM will also be useful for the immunophenotypic characterization of the expanded NK cell preparations that will be developed in Project 2.